GA-ASI Completes Full-Scale Fatigue Test on MQ-9B for Second Lifetime

14.10.2024 13:00:00 CEST | ACCESS Newswire | Press release

Share

SAN DIEGO, CA / ACCESSWIRE / October 14, 2024 / On Sept. 30, 2024, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed a major milestone with the full-scale fatigue testing of an MQ-9B Remotely Piloted Aircraft (RPA). The team completed the "second lifetime" of fatigue testing, which is equivalent to 80,000 operating hours and represents an important step in validating the design of the airframe system. The testing is part of the aircraft certification to NATO standard STANAG 4671, where the aircraft will ultimately be tested through three lifetimes, thereby proving the 40,000-hour lifetime of the airframe.

The full-scale fatigue test simulates the aircraft's design service through the application of repeated structural loading on the assembled airframe. The testing identifies any potential structural deficiencies ahead of fleet usage and assists in developing inspection and maintenance schedules for the airframe. The results of the test will be used as part of the documentation for certification and will form the basis for in-service inspections of structural components.

MQ-9B is GA-ASI's most advanced RPA and includes the SkyGuardian® and SeaGuardian® models as well as the new Protector RG Mk1 that is currently being delivered to the United Kingdom Royal Air Force (RAF).

"Full-scale fatigue testing is an integral part of validating the airframe design and a key input for the certification of the airframe prior to entering service," said Chris Dusseault, vice president of MQ-9B in Europe. "The completion of the fatigue test builds confidence for our MQ-9B customers that the SkyGuardian/SeaGuardian meets the stringent design rigor and is mature at Entry into Service."

The testing is the validation of years of design and analysis efforts. This is the second of three lifetimes of testing for the airframe. Two of the lifetimes simulate the operation of an aircraft under normal conditions, and the third has intentional damage inflicted on the airframe's critical components to demonstrate its resistance to operational damage that may occur over the lifetime of the air vehicle.

Testing was conducted from Jan. 31, 2024, through Sept. 30, 2024, at Wichita State University's National Institute for Aviation Research in Wichita, Kansas. The airframe tested is a production airframe purpose-built to support the test campaign.

In addition to the RAF, contracts have been signed for MQ-9B with Belgium, Canada, Japan, Taiwan and the U.S. Air Force in support of the Special Operations Command. The Japan Coast Guard is currently operating the SeaGuardian for maritime operations, and the Japan Maritime Self-Defense Force (JMSDF) selected SeaGuardian for its Medium-Altitude, Long-Endurance (MALE) RPA System Trial Operation Project.

About GA-ASI

General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.

For more information, visit www.ga-asi.com.

Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.

Contact Information

GA-ASI Media Relations
asi-mediarelations@ga-asi.com

SOURCE: General Atomics Aeronautical Systems, Inc.

View the original press release on newswire.com.

General Atomics

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release

Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica

Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release

CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a

Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in

CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release

TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr

Formerra and Evonik Expand Distribution Partnership for Healthcare Grades2.2.2026 15:00:00 CET | Press release

Agreement Expands Access to Evonik's CARE Brand Medical Grades in the U.S. and Canada ROMEOVILLE, ILLINOIS / ACCESS Newswire / February 2, 2026 / Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik's CARE brand healthcare grades into Formerra's medical portfolio. Covering the United States and Canada, the agreement creates new access points for high-performance polyamides used in essential healthcare applications. This expansion kicks off at MD&M West 2026 this week, and underscores both companies' commitment to supporting the healthcare market with high-performance materials, responsive service, and continuity of supply. It also builds on the companies' two-year partnership, which introduced Evonik's VESTAMID® and TROGAMID® families to Formerra's engineered materials lineup. With this expansion, Formerra will support Evonik healthcare grades designed for fluid handling, drug delivery, diagnostic systems, surgi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye